ArticleThe Canadian journal of urology2026
External validation of the heidenreich criteria for patients with post-chemotherapy residual masses of non-seminomatous germ cell tumor.
Article in The Canadian journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesResidual Disease after adjuvant chemotherapy for non-seminomatous germ cell tumor (NSGCT) poses a significant clinical challenge and difficulties in tailored management. This study aimed to externally validate the Heidenreich criteria among patients eligible for unilateral post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) for residual masses of NSGCT.
methodsFor validation, these criteria were retrospectively applied in 23 patients undergoing PC-RPLND for residual masses of NSGCTs. In patients qualified for unilateral-modified PC-RPLND according to the Heidenreich criteria but treated with fully bilateral dissection, pathological reports were evaluated to identify teratoma or active cancer cells inside the contralateral field. Patients treated with unilateral-modified PC-RPLND were followed to identify relapse within the contralateral field.
resultsOf those 23 patients included, 6 (26.1%) and 17 (73.9%) patients could have been treated with unilateral-modified or fully bilateral template dissection, according to the Heidenreich algorithm, respectively. Within a median follow-up of 85.4 months (IQR, 49.0-165.4), 4 (17.4%) and 2 (8.7%) retroperitoneal and distant recurrences occurred, respectively. Among these, 2 patients (40.0%) were treated with fully bilateral template resection. One patient (4.3%) experienced both distant and retroperitoneal recurrence. Of the 6 patients with an indication for a unilateral-modified PC-RPLND, one patient (16.7%) presented an in-field retroperitoneal recurrence. No recurrences were observed in the contralateral field when the unilateral-modified template dissection would have been performed according to the Heidenreich criteria.
conclusionsThe retrospective application of the Heidenreich criteria in our cohort correctly classified our patients, facilitating a tailored selection for sparing a surgical procedure without interfering with oncological outcomes and potentially minimizing early and late complications.
Indexed as
Identifiers
42415580What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.